WEBULL
News
XNCR
11.59
-0.26%
-0.03
Weekly Report: what happened at XNCR last week (0202-0206)?
Weekly Report · 5d ago
Xencor (XNCR) Gets a Buy from Truist Financial
TipRanks · 02/04 12:58
Weekly Report: what happened at XNCR last week (0126-0130)?
Weekly Report · 02/02 09:05
Weekly Report: what happened at XNCR last week (0119-0123)?
Weekly Report · 01/26 09:05
Weekly Report: what happened at XNCR last week (0112-0116)?
Weekly Report · 01/19 09:05
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 01/12 15:20
Weekly Report: what happened at XNCR last week (0105-0109)?
Weekly Report · 01/12 09:05
XENCOR INC <XNCR.O>: PIPER SANDLER RAISES TARGET PRICE TO $33 FROM $30
Reuters · 01/09 16:08
U.S. RESEARCH ROUNDUP-Ardelyx, RPM International, Trubridge
Reuters · 01/09 07:31
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR)
TipRanks · 01/08 21:20
XENCOR INC: EXPECTS TO HAVE SUFFICIENT CASH RESOURCES TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS THROUGH 2028
Reuters · 01/08 13:07
XENCOR INC: ENDED Q4 2025 WITH UNAUDITED CASH, CASH EQUIVALENTS AND MARKETABLE DEBT SECURITIES EXPECTED TO BE ABOUT $611 MLN
Reuters · 01/08 13:07
Xencor expects cash resources to fund operations through 2028
Reuters · 01/08 13:02
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
Barchart · 01/08 07:01
Xencor price target raised to $20 from $17 at BofA
TipRanks · 01/06 15:30
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR)
TipRanks · 01/06 12:46
XENCOR INC <XNCR.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $20 FROM $17
Reuters · 01/06 12:13
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure
Reuters · 01/06 07:53
Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy
Seeking Alpha · 01/05 15:19
Weekly Report: what happened at XNCR last week (1229-0102)?
Weekly Report · 01/05 09:05
More
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.